Bellicum pharmaceuticals, inc. (BLCM)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Cash flows from operating activities:
Net income (loss)

-112,477

-98,036

-91,779

-69,241

-48,548

-83,965

-7,969

Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation

7,338

13,824

13,569

12,337

8,409

911

391

Depreciation and amortization expense

7,175

6,698

-

-

-

-

-

Loss on extinguishment of debt

-

-

-1,786

0

0

-

-

(Gain)/Loss on disposal of property and equipment

-

-

11

-10

-42

0

0

Change in fair value of warrant and private placement option liabilities

19,192

0

-

-

-

-

-

Impairment of intangible assets

2,064

0

-

-

-

-

-

Depreciation and amortization expense

-

-

3,564

2,306

1,199

667

587

Amortization of discount on investment securities, net

30

-94

-302

-539

-573

0

0

Amortization of right-of-use assets

1,331

0

-

-

-

-

-

Accretion of lease liability

-804

276

102

119

94

89

-

Amortization of lease liability

-

-

-

-

-

-

-95

Amortization of deferred issuance costs

885

886

774

422

0

0

-

Loss on disposition of fixed assets

-6

-10

-

-

-

-

-

Warrant and private placement option issuance costs

3,047

0

-

-

-

-

-

Loss on disposition of investment securities

-

-

-

0

-33

0

0

Interest expense converted into preferred stock

-

-

-

-

-

-

3

Change in fair value of warrant liability

-

-

-

-

-

24,371

0

Changes in operating assets and liabilities:
Changes in operating assets and liabilities:
Accounts receivable, interest and other receivables

-606

589

-14

-106

142

-448

745

Prepaid expenses and other assets

1,096

-1,070

930

-885

1,067

1,068

-592

Other assets

-

-

95

-47

185

-339

287

Accounts payable

-1,131

460

-512

931

897

659

-1

Accrued liabilities and other

-2,300

2,197

-3,667

1,336

2,778

225

698

Deferred revenue

-2,983

-1,120

4,103

-

-

-

-

Deferred revenue

-

-

-

0

-13

13

-1,039

Deferred rent

-

-

-

0

859

5

14

Deferred manufacturing costs

-

-

-

0

-467

176

239

Net cash used in operating activities

-77,569

-74,782

-72,984

-50,441

-35,726

-57,308

-7,612

Cash flows from investing activities:
Purchases of investment securities

-

-

54,895

33,276

101,649

0

0

Cash flows from investing activities:
Purchases of investment securities

0

59,335

-

-

-

-

-

Proceeds from sale of investment securities

49,379

71,362

63,737

42,548

20,617

0

0

Proceeds on disposition of equipment

-

-

39

0

0

-

-

Purchases of property and equipment

522

1,617

12,134

7,220

5,421

804

366

Net cash (used in) provided by investing activities

48,857

10,410

-3,253

2,052

-86,453

-804

-366

Cash flows from financing activities:
Proceeds from issuance of stock from employee stock purchase plan

98

205

-

-

-

-

-

Proceeds from debt

-

-

45,000

20,000

0

386

-

Payment on debt

-

-

32,688

0

0

1,187

-

Proceeds from issuance of common stock, net

-

-

64,860

0

0

160,609

0

Proceeds from issuance of common stock in a public offering, net

8,977

64,860

-

-

-

-

-

Proceeds from issuance of redeemable convertible preferred stock in a public offering, net

22,944

0

-

-

-

-

-

Proceeds from issuance of warrants in a public offering, net

30,888

0

-

-

-

-

-

Proceeds received from private placement option, net

11,152

0

-

-

-

-

-

Proceeds from issuance of stock from employee stock purchase plan

-

-

293

369

347

0

-

Proceeds from exercise of stock options

76

3,300

1,486

773

482

0

0

Proceeds from notes payable

-

-

-

-

-

-

3,500

Payments of Debt Issuance Costs

-

-

150

199

0

0

-

Payment on financing lease obligations

47

31

23

15

4

0

0

Payment of issuance costs on common stock

0

195

292

0

7

14,242

0

Proceeds from issuance of preferred stock

-

-

-

-

-

62,320

13,671

Payment of issuance costs on preferred stock

-

-

-

-

-

3,524

7

Proceeds from exercise of preferred warrants

-

-

-

-

-

39,145

0

Proceeds from exercise of common warrants

-

-

-

-

-

249

0

Payment for repurchase of common stock

-

-

-

-

-

5,056

0

Payment of preferred dividends

-

-

-

-

-

155

0

Proceeds from line of credit or notes payable or debt

-

-

-

-

-

-

550

Payments on line of credit

-

-

-

-

-

-

200

Net cash (used in) provided by financing activities

74,088

68,109

78,486

20,928

818

238,546

17,514

Effect of exchange rate changes on cash

-228

-98

-

-

-

-

-

EFFECT OF EXCHANGE RATE CHANGES ON CASH

-

-

0

-

-

-

-

Net change in cash, cash equivalents, and restricted cash

45,148

3,639

2,249

-

-

-

-

NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

-

-

-

-27,461

-121,361

180,434

-

NET CHANGE IN CASH AND CASH EQUIVALENTS

-

-

-

-

-

-

9,536

Supplemental cash flow information:
Cash paid during the period for interest

3,201

3,025

2,951

-

-

-

-

Interest paid

-

-

-

1,136

0

1,767

47

Non-cash investing and financing activities:
Non-cash investing and financing activities:
Purchases of property and equipment in accounts payables and accrued liabilities

0

27

872

3,533

139

0

0

Financing leases incurred for equipment

167

0

-

-

-

-

-

Conversion of redeemable preferred stock into common stock

1,476

0

-

-

-

-

-

Reclassification of property and equipment, net to assets held for sale

12,039

0

-

-

-

-

-

Leasehold improvements paid by landlord

-

-

-

1,139

0

0

-

Accrued debt issuance costs

-

-

3,045

1,390

0

0

-

Capital lease obligations incurred for equipment

-

-

23

46

135

0

0

Conversion of notes payable into preferred stock

-

-

-

-

-

-

3,500

Preferred stock dividends paid in common stock

-

-

-

-

-

3,196

0

Dividends accreted on preferred stock

-

-

-

-

-

1,432

1,094